Immune Checkpoint Inhibitors in Glioblastoma Treatment
Author Information
Author(s): Baskaran Archit Bharathwaj, Kozel Olivia A., Venkatesh Omkar, Wainwright Derek A., Sonabend Adam M., Heimberger Amy B., Lukas Rimas Vincas
Primary Institution: The University of Chicago
Hypothesis
Can immune checkpoint inhibitors improve treatment outcomes for glioblastoma patients?
Conclusion
Immune checkpoint inhibitors have not yet shown clear evidence of efficacy in glioblastoma treatment.
Supporting Evidence
- 117 clinical trials were identified, with four being phase 3.
- Most trials involved PD-1 or CTLA-4 blockade.
- Large trials showed no improvement in overall survival or progression-free survival.
- Biomarker analyses suggest some patients may benefit from these treatments.
Takeaway
This study looks at how well certain cancer treatments work for brain tumors called glioblastomas, and so far, they haven't been very helpful.
Methodology
A systematic review of clinical trials investigating immune checkpoint inhibitors in glioblastoma from 1950 to July 2024.
Limitations
The review only included agents with FDA approval, potentially missing other relevant treatments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website